Newly diagnosed LCH children may receive cytarabine treatment
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This Phase 3 trial tests a treatment plan that includes cytarabine for children newly diagnosed with LCH (a rare condition where abnormal immune-related cells form lesions). It may help control the disease while comparing outcomes with a cytarabine-based protocol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under 18 years old
- Have a new LCH diagnosis confirmed by lab tests on a tissue sample
- No HIV infection, and no congenital (present-from-birth) immune system weakness
- No history of organ transplant
- No prior cancer treatments such as chemotherapy, targeted therapy, or radiation (if steroids were used before, the total dose must be below a set limit)
- Not have a severe, overwhelming infection with an expected life span under 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug called luvometinib, either alone or with a standard chemotherapy drug (cytarabine), for people with Langerhans cell histiocytosis. The goal is to see if adjusting the treatment based on your response can help control the disease.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This trial tests whether taking a steroid pill (prednisone) by mouth can help children and teenagers with bone-only LCH. It is for people who do not need surgery and can swallow pills.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.